MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
Completed · Phase 2
Conditions studied: Acute Myelogenous Leukemia
In brief
A phase II trial of CD3/CD19 depleted, IL-15 activated, donor natural killer (NK) cells in adults and subcutaneous IL-15 given after a preparative regimen for the treatment of relapsed or refractory acute myelogenous leukemia (AML). The primary objective is to study the potential efficacy of NK cells and IL-15 to achieve complete remission while maintaining safety.
Key facts
- Study ID
- NCT02395822
- Run by
- Masonic Cancer Center, University of Minnesota
- People needed
- 17
- Starts
- 2015-10-01
- Expected to finish
- 2016-12-01
- Last updated by the study team
- 2018-02-20
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Masonic Cancer Center at University of Minnesota — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.